Home         Forums  

Go Back   Marrowforums > Treatments > Drugs and Drug Treatments
Register FAQ Search Today's Posts Mark Forums Read

Drugs and Drug Treatments ATG, Cyclosporine, Revlimid, Vidaza, Dacogen, ...

Reply
 
Thread Tools Search this Thread
  #1  
Old Fri Aug 29, 2008, 04:26 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Thumbs up About treatment with Revlimid (lenalidomide) and EPO

Hi all,
Here is a thesis about anemia in MDS patients. There is interesting info about Revlimid and up-regulation of a tumor suppressor gene:
http://diss.kib.ki.se/2008/978-91-7409-100-7/
Kind regards
Birgitta-A
Reply With Quote
  #2  
Old Fri Aug 29, 2008, 11:48 AM
Neil Cuadra Neil Cuadra is offline
Owner
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 2,553
I didn't know the term "up-regulation" so I had to look it up.

It means that a cell responds to an external factor, like a drug, by increasing the amount of a protein, enzyme, or other component of the cell. Sometimes that's the desired effect of a drug, while in other cases down-regulation (a decrease) is the desired effect.

If I understand the report correctly, it concludes that lenalidomide (Revlimid) up-regulates the gene called SPARC, which suppresses tumors. This gene normally resides at the 5q location that is missing in 5q- syndrome.
Reply With Quote
  #3  
Old Sat Aug 30, 2008, 06:02 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Revlimid

Hi Neil,
Yes, and the important issues in Jäderlunds thesis is that the researchers are trying to make a pre-treatment risk-stratification.

We already know much about which patients that will respond to EPO like Aranesp and drugs like Neupogen (these findings are not new):
1 Patients with a transfusion need less than 2 units of packed red blood cells a month.
2 Patients with a Serum-EPO less than 500 U/l
A patient that have both these variables will respond in 74 % of the cases, a patient with one of these variables in 23 % of the cases and patients without these variables in 7 % of the cases.

Then we hope that the researchers will be able to assess the expression of individual genes especially the SPARC gene expression in all patients. If the SPARC expression levels are increased by Revlimid the patients will respond to the treatment.
Kind regards
Birgitta-A
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Abstracts from the EHA Conference Birgitta-A News and Events 2 Wed May 22, 2013 03:02 PM
Accepted into Campath Trial at NIH Greg H Drugs and Drug Treatments 279 Wed Aug 31, 2011 09:44 PM


All times are GMT -4. The time now is 04:44 PM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org